I realize that sample size is hard for BTO people, but Natera sold more tests this quarter than BTO did in the past two years. Genetics billing is complex and when you do it properly it’s confusing to patients because insurance companies suck. As BTO follows the “just get the kit in and don’t worry about being in network or charging properly” thing that Progenity did to try to get volume it all comes around. Noticed that BTO is having a lot more billing issues these days. We hear it in the field. Sounds like someone is trying to avoid the Progenity trap….but that means pissed off patients and a whole lot of headache. Even better your billing message is a hot mess. Sounds like the reps don’t even know what it is.
Really excited about the Natera single gene…that should take a big enough bite that BTO and their lack of cash flow will need to go to the well again for another round of funding pushing that IPO back another year while you lose market share.
I would think twice about joining BTO just yet. They overpay base salaries have low growth goals for a reason. That’s why people don’t leave. It’s easy and you can make a little money. If they make it through the year unscathed after our army of reps rolls out a superior product with better technology and actual data behind it, then I would absolutely consider the jump. BUT that seems unlikely. Even if they can get a 14 gene version out in April (with zero data behind it)
